# Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy

> **NCT02205372** · PHASE1,PHASE2 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 31 (actual)

## Conditions studied

- Diabetic Nephropathy

## Interventions

- **DRUG:** MT-3995
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02205372
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2015-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02205372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02205372, "Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT02205372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*